Baas P - Search Results

1

Diagnostic validation and interpretation of longitudinal circulating biomarkers using a biomarker response characteristic plot.

Moritz R, Muller M, Korse CM, van den Broek D, Baas P, van den Noort V, Ten Hoeve JJ, van den Heuvel MM, van Rossum HH. Moritz R, et al. Among authors: baas p. Clin Chim Acta. 2018 Dec;487:6-14. doi: 10.1016/j.cca.2018.09.015. Epub 2018 Sep 8. Clin Chim Acta. 2018. PMID: 30201371

2

Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer.

Muller M, Hoogendoorn R, Moritz RJG, van der Noort V, Lanfermeijer M, Korse CM, van den Broek D, Ten Hoeve JJ, Baas P, van Rossum HH, van den Heuvel MM. Muller M, et al. Among authors: baas p. Tumour Biol. 2021;43(1):115-127. doi: 10.3233/TUB-211504. Tumour Biol. 2021. PMID: 34219680 Free article. Clinical Trial.

3

Non-invasive diagnosis of pleural malignancies: the role of tumour markers.

van den Heuvel MM, Korse CM, Bonfrer JM, Baas P. van den Heuvel MM, et al. Among authors: baas p. Lung Cancer. 2008 Mar;59(3):350-4. doi: 10.1016/j.lungcan.2007.08.030. Epub 2007 Oct 22. Lung Cancer. 2008. PMID: 17933420

4

Chemoradiation therapy in nonsmall cell lung cancer.

Baas P, Belderbos JS, van den Heuvel M. Baas P, et al. Curr Opin Oncol. 2011 Mar;23(2):140-9. doi: 10.1097/CCO.0b013e328341eed6. Curr Opin Oncol. 2011. PMID: 21178617 Review.

5

eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer.

Buma AIG, Muller M, de Vries R, Sterk PJ, van der Noort V, Wolf-Lansdorf M, Farzan N, Baas P, van den Heuvel MM. Buma AIG, et al. Among authors: baas p. Lung Cancer. 2021 Oct;160:36-43. doi: 10.1016/j.lungcan.2021.07.017. Epub 2021 Aug 3. Lung Cancer. 2021. PMID: 34399166 Free article.

6

Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.

Schouwink H, Korse CM, Bonfrer JM, Hart AA, Baas P. Schouwink H, et al. Among authors: baas p. Lung Cancer. 1999 Jul;25(1):25-32. doi: 10.1016/s0169-5002(99)00044-6. Lung Cancer. 1999. PMID: 10466859

7

An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival.

Korse CM, Taal BG, Bonfrer JMG, Vincent A, van Velthuysen ML, Baas P. Korse CM, et al. Among authors: baas p. Ann Oncol. 2011 Dec;22(12):2625-2630. doi: 10.1093/annonc/mdr007. Epub 2011 Mar 17. Ann Oncol. 2011. PMID: 21415235 Free article.

8

Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.

de Vries R, Muller M, van der Noort V, Theelen WSME, Schouten RD, Hummelink K, Muller SH, Wolf-Lansdorf M, Dagelet JWF, Monkhorst K, Maitland-van der Zee AH, Baas P, Sterk PJ, van den Heuvel MM. de Vries R, et al. Among authors: baas p. Ann Oncol. 2019 Oct 1;30(10):1660-1666. doi: 10.1093/annonc/mdz279. Ann Oncol. 2019. PMID: 31529107 Free article.

9

Cyfra 21-1 and TPA as markers in malignant mesothelioma.

Bonfrer JM, Schouwink JH, Korse CM, Baas P. Bonfrer JM, et al. Among authors: baas p. Anticancer Res. 1997 Jul-Aug;17(4B):2971-3. Anticancer Res. 1997. PMID: 9329578

10

Evaluation of (18)F-FDG PET-CT for differentiation of pulmonary pathology in an approach of outpatient fast track assessment.

Aukema TS, Valdés Olmos RA, Klomp HM, Teertstra HJ, Belderbos JS, Vogel WV, Baas P, Burgers SA, van den Heuvel MM. Aukema TS, et al. Among authors: baas p. J Thorac Oncol. 2009 Oct;4(10):1226-30. doi: 10.1097/JTO.0b013e3181b2b782. J Thorac Oncol. 2009. PMID: 19687763 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

592 results

Search Page